Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21528004 | 1.00 | LTA4H (0.33) | LTA4HPARP1CXCR4 | |
| SCHEMBL21527957 | 1.00 | LTA4H (0.33) | LTA4HPARP1CXCR4 | |
| Hydrochloric Acid SCHEMBL6782514 | 0.98 | LTA4H (0.32) | LTA4HPARP1CXCR4 | |
| SCHEMBL2915880 | 0.87 | CXCR4 (0.39) | CXCR4 | |
| SCHEMBL2916954 | 0.80 | — | — | |
| SCHEMBL10829471 | 0.80 | — | — | |
| SCHEMBL8121741 | 0.78 | LTA4H (0.31) | LTA4HPARP1 | |
| SCHEMBL2916791 | 0.78 | CXCR4 (0.36) | LTA4HPARP1CXCR4 | |
| SCHEMBL26628972 | 0.78 | CXCR4 (0.32) | CXCR4 | |
| Hydrochloric Acid SCHEMBL6785847 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0988292-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-03-29 | — | — | EP | claimed |
| WO-1998056771-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-12-17 | — | — | WO | claimed |
| US-12544448-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250108117-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-04-03 | — | — | US | disclosed |
| US-12234244-B2 | Substituted piperazines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2025-02-25 | — | — | US | disclosed |
| US-12187746-B2 | C26-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2025-01-07 | — | — | US | disclosed |
| CN-119059961-A | Cyclic fatty polyamine compound, preparation method and application thereof, and cyclic fatty polyamine combined solution | 大连理工大学 | 2024-12-03 | — | — | CN | disclosed |
| US-20240352028-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2024-10-24 | — | — | US | disclosed |
| EP-3788050-B1 | C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | REVOLUTION MEDICINES INC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-12048749-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20240166667-A1 | C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-05-23 | — | — | US | disclosed |
| EP-0934304-B1 | 2-PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | CELLTECH THERAPEUTICS LTD (GB) | 2003-02-26 | — | — | EP | disclosed |
| US-20030022886-A1 | Immoglobulin E (IgE) antibody production inhibitor; treating allergic immune diseases such as asthma, dermatitis, inflammatory bowel disease and allergic opthalmopathy | KOWA CO., LTD. (JP) | 2003-01-30 | — | — | US | disclosed |
| WO-2003004488-A1 | INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
| US-6114333-A | 2-Pyrimidineamine derivatives and processes for their preparation | CELLTECH THERAPEUTICS LTD. (GB) | 2000-09-05 | — | — | US | disclosed |
| EP-0934304-A1 | 2-PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | CELLTECH THERAPEUTICS LIMITED (GB) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998018782-A1 | 2-PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | CELLTECH THERAPEUTICS LIMITED (GB) | 1998-05-07 | — | — | WO | disclosed |
| US-5210193-A | Bactericide | AMERICAN CYANAMID COMPANY (US) | 1993-05-11 | — | — | US | disclosed |
| US-4940710-A | 7-(substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1990-07-10 | — | — | US | disclosed |
| EP-0230053-A2 | 7-(Substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1987-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12234244-B2 | Substituted piperazines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | LTA4H 4448/4885PARP1 1612/4885CXCR4 1970/4885 |
| US-20030022886-A1 | Immoglobulin E (IgE) antibody production inhibitor; treating allergic immune diseases such as asthma, dermatitis, inflammatory bowel disease and allergic opthalmopathy | IGLV6-57, IL5, IGSF11 | LTA4H 587/4885PARP1 3477/4885CXCR4 1233/4885 |
| US-20250108117-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | MTOR, RICTOR, RPTOR | LTA4H 4132/4885PARP1 1568/4885CXCR4 2592/4885 |
| US-12048749-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | LTA4H 4132/4885PARP1 1568/4885CXCR4 2592/4885 |
| US-12187746-B2 | C26-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | LTA4H 4199/4885PARP1 1174/4885CXCR4 3493/4885 |
| US-20240352028-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | LTA4H 4244/4885PARP1 1495/4885CXCR4 862/4885 |
| US-20240166667-A1 | C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | MTOR, RICTOR, RPTOR | LTA4H 4199/4885PARP1 1174/4885CXCR4 3493/4885 |
| US-12544448-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | RICTOR, MTOR, MLST8 | LTA4H 4756/4885PARP1 2516/4885CXCR4 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.